Cancidas (previously Caspofungin MSD) (caspofungin)
- Region
- 🇪🇺 EU
- Active substance
- caspofungin
- Status
- Authorised
- Therapeutic area
- Candidiasis; Aspergillosis
- CHMP opinion
- Thu 26 Jul 2001
- EU approval
- Tue 23 Oct 2001
- Application
- EMEA/H/C/000379
- ATC
- J02AX04
- Official record
- www.ema.europa.eu
Indication
Treatment of invasive candidiasis in adult or paediatric patients; treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy; empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Caspofungin Accord Expired · Accord Healthcare S.L.U.
Follow Cancidas (previously Caspofungin MSD)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.